MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
OTCMQB
0.180
+0.002
+0.84%
Closed 15:58 06/18 EDT
OPEN
0.167
PREV CLOSE
0.179
HIGH
0.190
LOW
0.165
VOLUME
505.01K
TURNOVER
89.38K
52 WEEK HIGH
0.766
52 WEEK LOW
0.100
MARKET CAP
74.57M
P/E (TTM)
-0.4702
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SGMO last week (0608-0612)?
Weekly Report · 4d ago
Deal Dispatch: Carlyle Buys Chung Ho Group, Second Nature Brands Acquires Tillamook Country Smoker, GoHealth Bankruptcy
Benzinga · 06/12 18:40
SANGAMO THERAPEUTICS ANNOUNCES EXPLORATION OF STRATEGIC ALTERNATIVES TO MAXIMIZE VALUE FOR STAKEHOLDERS
Reuters · 06/08 12:05
Weekly Report: what happened at SGMO last week (0601-0605)?
Weekly Report · 06/08 09:02
Weekly Report: what happened at SGMO last week (0525-0529)?
Weekly Report · 06/01 09:03
Sangamo price target lowered to $5 from $10 at H.C. Wainwright
TipRanks · 05/26 15:59
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/26/26?
TipRanks · 05/26 14:04
Vanguard Total Stock Market (VTI) ETF Latest Update — What Investors Should Know Now
TipRanks · 05/25 13:47
More
About SGMO
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Webull offers Sangamo Therapeutics Inc stock information, including OTCMQB: SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.